Asuragen to Develop BCR-ABL1 RT-qPCR Testing Calibrators, Software for Novartis | GenomeWeb

Asuragen said this week that it has entered into an exclusive agreement with Novartis to develop software to aid laboratories with standardization of BCR-ABL1 RT-qPCR testing to the International Scale.

Under the deal, Asuragen will develop Armored RNA Quant BCR-ABL1 RNA International Scale calibrators and laboratory software reporting tools to help laboratories standardize testing when treating Philadelphia chromosome-positive chronic myelogenous leukemia patients with Novartis' Gleevec.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.